J of IMAB 2012; 18(1):231-238
NEW STRATEGIES IN LIVER SURGERY FOR IV STAGE METASTATIC COLORECTAL CANCER.
Nikola Y. Kolev, Anton Y. Tonev, Valentin L. Ignatov, Georgi H. Ivanov, Aleksander K. Zlatarov, Georgi Todorov, Velian Platikanov, Krasimir D. Ivanov
1st Clinic of Surgery, University Hospital "St. Marina", Varna, Bulgaria.

ABSTRACT:
With recent advances in chemotherapy, traditional clinicopathological factors should not be used to exclude otherwise resectable patients from surgery. Pathological or clinical response to chemotherapy has become valuable in determining the treatment for individual patients. Portal vein embolization and two-stage operation with ablative therapy and preoperative chemotherapy should be considered for unresectable liver metastases located in a liver remnant that is at the minimum volume required for survival. The recent E0RTC 40983 trials regarding preoperative chemotherapy for resectable CLM have failed to demonstrate a clear significant advantage. However, patients with a low clinical risk score for the recurrence, such as several metastases of less than 4 cm, and who are fit candidates for liver resection are often offered immediate surgery. Patients at high clinical risk should also be considered for neoadjuvant chemotherapy. One forthcoming and appealing strategy is to adapt postoperative treatment according to tumor response as evaluated by neoadjuvant chemotherapy or by the presence of individual tumor biomarker such as the Kras mutation or single-nucleotide polymorphisms. This could avoid the overtreatment of nonresponsive patients and enable a more tailored approach to treat an individual patient’s disease. The treatment paradigm for CLM is rapidly changing with the development of newer anticancer chemotherapeutic agents.

Key words: colorectal cancer, liver metastases.

- Download FULL TEXT ( PDF 163 KB )
Please cite this article as: Kolev NY, Tonev AY, Ignatov VL, Ivanov GH, Zlatarov AK, Todorov G, Platikanov V, Ivanov KD. NEW STRATEGIES IN LIVER SURGERY FOR IV STAGE METASTATIC COLORECTAL CANCER. J of IMAB. 2012; 18(1):231-238. doi: 10.5272/jimab.2012181.231

REFERENCES:
1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al: Cancer statistics, 2004. CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. [PubMed]
2. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history.Br J Surg, 1990Nov;77(11):1241-1246. [PubMed]
3. Venook A: Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist. 2005 Apr;10(4):250-261, [PubMed] [CrossRef]
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 Jun 3;350(23):2335-2342, [PubMed]
5. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patientsscreened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg, 2004 Sep;240(3):438-447 [PubMed]
6. Pawlik TM, Abdalla EK, Ellis LM, Vauthey JN, Curley SA. Debunking dogma: surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg, 2006Feb;10(2):240-248 [PubMed] [CrossRef]
7. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg, 2005 May;241(5):715-724. [PubMed]
8. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg, 2004 Jun;239(6):818-825. [PubMed]
9. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg, 2002 Jun;235(6):759-766. [PubMed]
10. Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg, 2001Jul;88(7):980-985. [PubMed] [CrossRef]
11. Akhurst T, Kates TJ, Mazumdar M, Yeung H, Riedel ER, Burt BM, et al: Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol, 2005 Dec 1;23(34):8713-8716. [PubMed] [CrossRef]
12. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH,  et al: Colorectal liver metastases: CT, MR imaging, and PET for diagnosis - meta-analysis. Radiology, 2005 Oct;237(1):123-131. Epub 2005 Aug 11. [PubMed] [CrossRef]
13. D'Angelica M, Fong Y, Weber S, Gonen M, DeMatteo RP, Conlon K, et al: The role of staging laparoscopy in hepatobiliary malignancy: prospective analysis of 401 cases. Ann Surg Oncol, 2003 Mar;10(2):183-189. [PubMed]
14. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol, 2006 Oct;13(10):1271-1280. Epub 2006 Sep 6. [PubMed] [CrossRef]
15. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol, 2006 Oct;13(10):1261-1268. Epub 2006 Sep 1. [PubMed] [CrossRef]
16. Kokudo N, Imamura H, Sugawara Y, Sakamoto Y, Yamamoto J, Seki M, Makuuchi M. Surgery for multiple hepatic colorectal metastases. JHepatobiliary Pancreat Surg, 2004 11(2):84-91. [PubMed] [CrossRef]
17. Vauthey JN, Pawlik TM, Abdalla EK, Arens JF, Nemr RA, Wei SH, et al: Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg, 2004 May;239(5):722-732. [PubMed]
18. Yamamoto J, Sugihara K, Kosuge T, Takayama T, Shimada K, Yamasaki S, et al: Pathologic support for limited hepatectomy in the treatment of liver metastases from colorectal cancer. Ann Surg, 1995  Jan;221(1):74-78. [PubMed]
19. Elias D, Cavalcanti A, Sabourin JC, Pignon JP, Ducreux M, Lasser P. Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol. 1998 Oct;69(2):88-93. [PubMed] [CrossRef]
20. Jaeck D. The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies. Ann Surg Oncol. 2003 Nov;10(9):1007-1011, [PubMed]
21. Elias D, Sideris L, Pocard M, Ouellet JF, Boige V, Lasser P, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004 Mar;11(3):274-280, [PubMed]
22. Watanabe I, Arai T, Ono M, Sugito M, Kawashima K, Ito M, et al. Prognostic factors in resection of pulmonary metastasis from colorectal cancer. Br J Surg 2003 Nov;90(11):1436-1440, [PubMed] [CrossRef]
23. Dômont J, Pawlik TM, Boige V, Rose M, Weber JC, Hoff PM, et al. Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. J Clin Oncol. 2005 May 1;23(13):3086-3093. [PubMed] [CrossRef]
24. Couinaud C: Le foie. Etudes anatomiques et churgicales, in Masson and Cie (eds). Paris, pp 469-479, 1957
25. Zorzi D, Mullen JT, Abdalla EK, Pawlik TM, Andres A, Muratore A, et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg. 2006 Jan;10(1):86-94, [PubMed] [CrossRef]
26. Makuuchi M, Hasegawa H, Yamazaki S: Intraoperative ultrasonic examination for hepatectomy. Jpn J Clin Oncol 1981 11:367-390.
27. Torzilli G, Montorsi M, Donadon M, Palmisano A, Del Fabbro D, Gambetti A, et al. "Radical but conservative" is the main goal for ultrasonography-guided liver resection: prospective validation of this approach. J Am Coll Surg 2005 Oct;201(4):517-528. [PubMed] [CrossRef]
28. Torzilli G, Del Fabbro D, Palmisano A, Donadon M, Bianchi P, Roncalli M, et al. Contrast-enhanced intraoperative ultrasonography during hepatectomies for colorectal cancer liver metastases. J Gastrointest Surg. 2005 Nov;9(8):1148-1153. [PubMed] [CrossRef]
29. Kooby DA, Stockman J, Ben-Porat L, Gonen M, Jarnagin WR, Dematteo RP, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003 Jun;237(6):860-869. [PubMed]
30. Okano T, Ohwada S, Nakasone Y, Sato Y, Ogawa T, Tago K, et al. Blood transfusion causes deterioration in liver regeneration after partial hepatectomy in rats. J Surg Res  2001 Dec;101(2):157-165. [PubMed] [CrossRef]
31. Hasegawa K, Takayama T, Orii R, Sano K, Sugawara Y, Imamura H, et al. Effect of hypoventilation on bleeding during hepatic resection: a randomized controlled trial. Arch Surg. 2002 Mar;137(3):311-315. [PubMed]
32. Melendez JA, Arslan V, Fischer ME, Wuest D, Jarnagin WR, Fong Y, et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J AmColl Surg, 1998 Dec;187(6):620-625. [PubMed]
33. Abdalla EK, Noun R, Belghiti J. Hepatic vascular occlusion: which technique? Surg Clin North Am, 2004 Apr;84(2):563-585. [PubMed] [CrossRef]
34. Makuuchi M, Mori T, Gunvén P, Yamazaki S, Hasegawa H. Safety of hemihepatic vascular occlusion during resection of the liver. Surg Gynecol Obstet. 1987 Feb;164(2):155-158. [PubMed]
35. Belghiti J, Noun R, Malafosse R, Jagot P, Sauvanet A, Pierangeli F, et al. Continuous versus intermittent portal triad clamping for liver resection: a controlled study. Ann Surg. 1995 Mar;229(3):369-375, [PubMed]
36. Torzilli G, Makuuchi M, Midorikawa Y, Sano K, Inoue K, Takayama T, et al. Liver resection without total vascular exclusion:hazardous or beneficial? An analysis of our experience. Ann Surg. 2001 Feb;233(2):167-175, [PubMed]
37. Aloia TA, Zorzi D, Abdalla EK, Vauthey JN. Two-surgeon technique for hepatic parenchymal transaction of the noncirrhotic liver using salinelinked cautery and ultrasonic dissection. Ann Surg. 2005 Aug;242(2):172-177. [PubMed]
38. Lesurtel M, Selzner M, Petrowsky H, McCormack L, Clavien PA. How should transection of the liver be performed?: a prospective randomized study in 100 consecutive patients: comparing four different transaction strategies. Ann Surg, 2005 Dec;242(6):814-822. [PubMed]
39. Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery. 1994 Oct;116(4):703-710, [PubMed]
40. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995 Jan-Feb;19(1):59-71. [PubMed]
41. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases of the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996 Apr 1;77(7):1254-1262, [PubMed]
42. Jaeck D, Bachellier P, Guiguet M, Boudjema K, Vaillant JC, Balladur P, et al. Longterm survival following resection of colorectal hepatic metastases. Association Franc¸aise de Chirurgie. Br J Surg. 1997 Jul;84(7):977-980. [PubMed]
43. Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM. Hepatic resections for metastatic colorectal cancer. Results in cure for some patients. Arch Surg. 1997 May;132(5):505-511. [PubMed]
44. Jenkins LT, Millikan KW, Bines SD, et al. Hepatic resection for metastatic colorectal cancer. Am Surg  1997 Jul;63(7):605-610, [PubMed]
45. Ambiru S, Miyazaki M, Isono T, Ito H, et al. Hepatic resection for colorectal metastases: analysis of prognostic factors. Dis Colon Rectum. 1999 May;42(5):632-639. [PubMed]
46. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-318. [PubMed]
47. Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000 Apr; 231(4):487-499, [PubMed]
48. Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg. 2001 Jul;88(7):980-985. [PubMed] [CrossRef]
49. Poston GJ. The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Eur J Surg Oncol. 2005 May;31(4):325-330. [PubMed]
50. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on respectability of hepatic colorectal metastases. J Am Coll Surg. 2005 Jun;200(6):845-853. [PubMed] [CrossRef]
51. Rubbia-Brandt L, Audard V, Sartoretti P, et al: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004 Mar;15(3):460-466 [PubMed] [CrossRef]
52. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. 2003 Dec;7(8):1034- 1044. [PubMed] [CrossRef]
53. Parikh AA, Gentner B, Wu TT, et al: Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003 Dec;7(8):1082-1088, [PubMed] [CrossRef]
54. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006 May 1;24(13):2065-2072, [PubMed] [CrossRef]
55. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002 Jun;137(6):675-680, [PubMed]
56. Azoulay D, Castaing D, Smail A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000 Apr;231(4):480-486, [PubMed]
57. Abdalla EK, Hicks ME, Vauthey JN: Portal vein embolization: rationale, technique and future prospects. Br J Surg. 2001 Feb;88(2):165-175. [PubMed] [CrossRef]
58. Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol. 2005 Jun;16(6):779-790. [PubMed]
59. Vauthey JN, Abdalla EK, Doherty DA, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl.2002 Mar;8(3):233-240, [PubMed] [CrossRef]
60. Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 2004 Oct;5(10):836-847. [PubMed] [CrossRef]
61. Kusaka K, Imamura H, Tomiya T, Makuuchi M. Factors affecting liver regeneration after right portal vein embolization. Hepatogastroenterology 2004 Mar-Apr;51(56):532-535. [PubMed]
62. Komori K, Nagino M, Nimura Y: Hepatocyte morphology and kinetics after portal vein embolization. Br J Surg 2006 Jun;93(6):745-751. [PubMed] [CrossRef]
63. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000 Dec;232(6):777-785. [PubMed]
64. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple andbilobar colorectal liver metastases. Ann Surg 2004 Dec;240(6):1037-1049. [PubMed]
65. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 2003 Oct;238(4):508-518. [PubMed]
66. Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006 May;141(5):460-467 [PubMed]
67. de Baère T, Risse O, Kuoch V, Dromain C, Sengel C, Smayra T, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol 2003 Sep;181(3):695-700. [PubMed]
68. Nikfarjam M, Muralidharan V, Christophi C. Altered growth patterns of colorectal liver metastases after thermal ablation. Surgery 2006 Jan;139(1):73-81. [PubMed] [CrossRef].

Accepted for publication: 18 September 2011
Issue published online: 02 March 2012

back to Online Journal